Login to Your Account



Other News To Note


Wednesday, May 4, 2011
AtheroNova Inc., of Irvine, Calif., will pursue an additional indication to address unmet needs in stroke prevention with a compound to treat intracranial atherosclerosis disease, regarded as a primary cause of ischemic stroke. AtheroNova is conducting two second-round preclinical studies evaluating the atherosclerotic plaque regression efficacy of the company's compounds.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription